HEPATOCELLULAR CANCER
Clinical trials for HEPATOCELLULAR CANCER explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CANCER trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets Hard-to-Treat liver cancers
Disease control TerminatedThis study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer when standard treatments failed. The goal was to see if the drugs could shrink tumors. The study was st…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:21 UTC
-
Experimental cancer drug trial halted after early testing
Disease control TerminatedThis study tested a new drug called TAK-500, alone or with pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Genetic mapping of GI cancers aims to match patients with targeted therapies
Knowledge-focused TerminatedThis study looked at genetic mutations in tumors from 565 people with cancers of the liver, bile ducts, gallbladder, pancreas, esophagus, or stomach. The goal was to see how often these mutations occur and whether they can help doctors choose more personalized treatments. The stu…
Matched conditions: HEPATOCELLULAR CANCER
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated May 26, 2026 04:19 UTC